Global Homocystinuria Market - 2023-2030

Global Homocystinuria Market - 2023-2030

Global Homocystinuria Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

Homocysteine and its metabolites accumulate excessively in a person's blood and urine as a result of HCU, which is caused by an inability to metabolize the amino acid methionine, a precursor to homocysteine. Patients experience a variety of symptoms, including bone abnormalities, intellectual impairments, and potentially fatal blood vessel obstructions.

Few therapeutic alternatives are available, and many patients must adhere to rigorous, restrictive diets. Increased public and professional awareness of homocystinuria is one of the key factors driving the market. Early and accurate diagnosis have been made possible by better knowledge of the symptoms of the condition and the availability of diagnostic testing.

Numerous nations have put in place newborn screening programs that examine infants for a number of hereditary diseases, including homocystinuria. The ability to quickly intervene and control the disease due to early discovery through neonatal screening can considerably enhance results.

Dynamics

Increasing Research Activities

In May 2023, Pegtibatinase, a brand-new experimental enzyme replacement medication, is being tested for the treatment of classical homocystinuria (HCU), and Travere Therapeutics, Inc. has published encouraging results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study. Four of the five patients in this cohort were assigned to the treatment group, which received 2.5 mg/kg of lyophilized pegtibatinase or a placebo twice weekly (BIW) in a blinded randomization.

A 67.1% mean relative decrease in total homocysteine (tHcy) from baseline and the maintenance of mean tHcy below the clinically significant threshold of 100 M over weeks 6 to 12 were the effects of pegtibatinase treatment in this highest dose cohort to date. Pegtibatinase has so far been generally well tolerated in the trial.

The Increasing Treatment Options

Pharmaceutical doses of pyridoxine, vitamin D, and extra folic acid and vitamin B12 supplementation are used to treat pyridoxine-responsive patients. More than 100 enzymes rely on vitamin B6 (pyridoxine), which is also involved in numerous metabolic pathways involving protein and fat. A cofactor is a type of ""helper molecule"" for our body's enzymes, which are in charge of critical functions.

The vitamin is necessary for the development of hemoglobin, the pigment of red blood cells, the immune system, and the brain system. The so-called pyridoxine hydrochloride or the pyridoxal phosphate (PLP) in its already-active state is typically present in dietary supplements. Pyridoxine, or vitamin B6, is typically found in medications as the white, crystalline compound pyridoxine hydrochloride (C8H12ClNO3), which is easily soluble in water. The prodrug pyridoxine is biotransformed in the body into the active PLP.

Increasing Focus Towards Classical Homocystinuria

Classical homocystinuria (HCU), a severe rare genetic condition that affects 1 in 200,000 to 335,00 births globally, is primarily brought on by mutations in the cystathionine-synthetase (CBS) gene. Homocysteine (Hcy), a byproduct of methionine (Met) metabolism, cannot be transformed into cystathionine in the absence of a functional CBS.

Total Hcy (tHcy), which comprises both circulating free Hcy and Hcy bound to serum proteins, is high and possibly hazardous in the presence of CBS deficiency; normal tHcy levels are below 15 M, whereas untreated patients frequently have tHcy values above 100 M. Patients may also have higher Met levels as a result of the methionine recycling pathway's interconversion of Met and Hcy. Although HCU patients may have elevated levels of Met, which is the normal human blood concentration, hypermethioninemia is thought to be benign at Met levels under 1000 M.

High Development Cost

Understanding the illness causes and prospective targets requires substantial research when developing a novel medication. To confirm the treatment strategy, preclinical testing in labs and on animals is required. To evaluate a new treatment's efficacy and safety in humans, clinical trials are crucial. There are several stages to these trials, and each one costs a lot of money. Due of the small patient populations, rare diseases may necessitate longer recruitment periods.

It takes significant documentation, testing, and compliance work to meet the regulatory criteria imposed by health authorities like the FDA or EMA, all of which add to expenses. Complex manufacturing procedures and quality control techniques are needed to produce medications at a high quality level, consistently, and in accordance with laws.

Small Patient Population

Homocystinuria is an uncommon disease that frequently has a tiny patient population. The small number of affected people provides difficulties, but it also raises special issues for pharmaceutical firms and healthcare providers. The rarity of the illness makes it challenging to enroll a sufficient number of individuals in clinical studies.

This may cause trial schedule extensions and development process delays. It can be difficult to get statistically meaningful data from a limited patient population, which has an impact on the reliability of clinical trial outcomes and the capacity to generalize results. Healthcare practitioners could lack experience and knowledge in recognizing and treating homocystinuria due to the disease's rarity.

For more details on this report – Request for Sample

Segment Analysis

The global homocystinuria market is segmented based on drug treatment, form, route of administration, distribution channel and region.

Betaine accounts for largest market share during the forecast period

Oral betaine (N, N, N-trimethylglycine) is administered as a methyl donor to provide an additional channel for the remethylation of HCy to methionine catalyzed by betaine-homocysteine methyl transferase if the tHCy target cannot be achieved with pyridoxine alone.

Due to this, the amount utilized (which in adults may be higher than the UK-licensed dose of 3 g twice daily) is the highest that allows for the maintenance of methionine at less than 1000 mol/L. A combination of pyridoxine and betaine alone can frequently provide appropriate and secure treatment for patients who are only partially responsive to pyridoxine.

Geographical Penetration

Infrastructure Development, Urbanization and Construction Projects

North America has been a dominant force in the global homocystinuria market. In order to cure homocystinuria, blood homocysteine levels must be kept under control. Taking a vitamin B6 supplement is typically part of the treatment. If one has classical homocystinuria that responds to vitamin B6, vitamin B6 administration can be sufficient to lower and regulate homocysteine levels.

In addition, in March 2023, in a contract with ANI Pharmaceuticals, Inc., Cosette Pharmaceuticals, Inc. acquired the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (""Betaine"") and started distributing to clients in March month.

Patients with homocystinuria, a rare genetic disorder in which the body accumulates too much homocysteine, utilize betaine. With this launch, a safe, effective, and easily accessible treatment alternative will be made available to patients with homocystinuria and the healthcare professionals who are providing care to those patients.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global Homocystinuria market. Due to lockdowns, the worry of virus transmission, and the diversion of resources, access to healthcare facilities was restricted during the pandemic. This might have delayed the diagnosis and start of treatment for those with homocystinuria. As the number of in-person visits decreased, telemedicine and virtual consultations became more popular.

Despite the fact that telemedicine made it easier to maintain continuity of care, it might not entirely replace the requirement for thorough in-person examinations, particularly for rare disorders. Due to difficulties in patient recruitment, site closures, and the redirection of resources into COVID-19 research, several clinical studies were postponed, stopped, or delayed. Data collection and trial progress were hindered by travel restrictions, limited access to healthcare institutions, and patient safety concerns.

Russia-Ukraine War Impact Analysis

The ability to provide medical care, diagnoses, and treatments including those for rare disorders like homocystinuria may be harmed or destroyed as a result of the conflict. The availability of specialized treatments for uncommon diseases may be impacted if healthcare resources are diverted to urgent care and emergency situations.

Homocystinuria sufferers may have trouble accessing healthcare because to their dislocation, a lack of resources, and interruptions in their continuity of care. Conflict-related disruptions may have an impact on efforts to discover novel therapies for rare diseases like homocystinuria.

By Drug Treatment
• Pyridoxine
• Betaine
• Folate
• Cobalamin

By Form
• Tablets
• Suspension
• Pills
• Capsules

By Route of Administration
• Oral
• Parenteral

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In May 2023, Eton Pharmaceuticals, Inc, a pharmaceutical company engaged in developing and commercializing treatments for rare diseases, reported the commercial availability of Betaine Anhydrous for Oral Solution 180 grams for the treatment of homocystinuria.

Competitive Landscape
The major global players in the market include Travere Therapeutics, Aeglea BioTherapeutics, Ginkgo Bioworks, Cosette Pharmaceuticals, Inc., Eton Pharmaceuticals, Inc., and Others.

Why Purchase the Report?
• To visualize the global homocystinuria market segmentation based on drug treatment, form, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of homocystinuria market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global homocystinuria market report would provide approximately 64 tables, 57 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies